The "Rani stock forecast" remains bullish as trading sentiment benefits from strong biotech ETF flows. Market indicators show RSI hovering near 55, implying room for upward momentum. Analysts suggest watching Q3 trial data as a decisive price driver in the coming weeks. To this end, Yang rates UCTT shares as Outperform (i.e. Buy) with a price target of $70, indicating a potential 76% upside within the next year. (To watch Yang’s track record, click here ) Wall Street analysts have issued reports on $RANI in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings. Technical analysis supports the bullish "Rani stock forecast", with Bollinger Bands showing a volatility expansion phase — often preceding large directional moves in biotech equities.
